首页|耳聋左慈丸治疗慢性分泌性中耳炎临床疗效及作用机制研究

耳聋左慈丸治疗慢性分泌性中耳炎临床疗效及作用机制研究

扫码查看
目的 观察耳聋左慈丸联合西医疗法治疗慢性分泌性中耳炎的临床疗效,并分析其作用机制。方法 选择2022年1月—2022年12月于医院耳鼻喉科治疗的200例慢性分泌性中耳炎患者,采用随机数字表法将上述患者分为对照组和试验组,每组100例,对照组患者予以西医常规治疗,试验组在对照组基础上予以耳聋左慈丸治疗。比较两组患者的临床疗效、症状和不良反应情况,以及治疗前后听力水平、耳积液炎症因子水平变化。结果 对照组患者的有效率为(80。00%,80/100),试验组患者的有效率为(90。00%,90/100),与对照组比较,试验组的有效率明显升高(P<0。05)。治疗前、治疗后1周两组患者的ETDQ-7无明显差异(P>0。05);治疗后3周后,试验组患者的ETDQ-7水平相较于对照组均明显下降(P<0。01)。干预完成后,试验组患者耳鸣、耳闷、听力下降以及鼓室积液等主要症状评分水平相较于对照组均明显降低(P<0。01)。干预完成后,与对照组患者比较,试验组患者0。5、1、2 kHz的纯音听阈明显降低,差异具有统计学意义(P<0。01)。干预前两组患者的耳积液炎症因子水平差异无统计学意义(P>0。05);干预完成后,试验组患者耳积液中IL-1β、IL-8以及TNF-α水平相较于对照组均明显下降(P<0。01)。干预过程中所有患者的主要不良反应有恶心呕吐、食欲不振、腹痛腹泻、头晕头痛等,两组患者的不良反应发生率差异无统计学意义(P>0。05)。结论 耳聋左慈丸联合西医疗法治疗慢性分泌性中耳炎具有良好的临床效果,提高患者听力水平,改善临床症状,抑制局部炎症反应,且无不良反应增加。
Study on Clinical Effect and Partial Mechanism of Erlong Zuoci Pills(耳聋左慈丸)in Treating Chronic Secretory Otitis Media
Objective To observe the clinical effect of Erlong Zuoci Pills(耳聋左慈丸)combined with conventional western medicine in the treatment of chronic secretory otitis media and to analyze its mechanism.Methods A total of 200 patients with chronic secretory otitis media treated in otolaryngology department of the hospital from January 2022 to December 2022 were se-lected and divided into control group and experimental group by random number table method,with 100 cases in each group.The patients in the control group were given conventional Western medicine treatment,and those in the experimental group were given Erlong Zuoci Pills on the basis of the control group.The clinical efficacy,symptoms and adverse reactions of the two groups were compared as well as the changes of hearing level and the levels of inflammatory factors in ear effusion before and after treatment.Results The effective rate of the control group was 80.00%(80/100)and that of the experimental group was 90.00%(90/100).Compared with that of the control group,the effective rate of the experimental group was significantly increased(P<0.05).There was no significant difference in the seven-item eustachian tube dysfunction questionnaire(ETDQ-7)between the two groups before treatment and 1 week after treatment(P>0.05).After 3 weeks of treatment,the ETDQ-7 level of the experimental group was significantly decreased compared with that of the control group(P<0.01).After the intervention,the scores of tinnitus,ear tightness,hearing loss and tympanic effusion in the experimental group were significantly decreased compared with those in the control group(P<0.01).After the intervention,compared with those of the control group,the pure tone hearing thresholds of 0.5,1 and 2 kHz in the experimental group were significantly decreased,and the difference was statistically significant(P<0.01).Before intervention,there was no significant difference in the levels of inflammatory factors in ear effusion between the two groups(P>0.05).After the intervention,the levels of interleukin-1β(IL-1β),interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in ear effusion of the experimental group were significantly decreased compared with those of the control group(P<0.01).During the intervention,the main adverse reactions of all patients included nausea,vomiting,loss of appetite,abdominal pain,diarrhea,dizziness and headache,and there was no significant difference in the incidence of adverse reactions be-tween the two groups(P>0.05).Conclusion Erlong Zuoci Pills combined with conventional Western medicine therapy in the treatment of chronic secretory otitis media has good clinical effect,and can improve the hearing level and the clinical symptoms,and inhibit the local inflammatory reaction of the patients,and there was no increased adverse reaction.

Erlong Zuoci Pills(耳聋左慈丸)chronic secretory otitis medialistening levelinflammatory cytokinesclinical researchmechanism of action

张俊、司远征、马赛、张乐

展开 >

南阳医学高等专科学校第一附属医院,河南南阳 473000

耳聋左慈丸 慢性分泌性中耳炎 听力水平 炎症因子 临床研究

国家中医药局中医药行业科研项目河南省卫生厅医学公益项目

20190833786120140341A

2024

中华中医药学刊
中华中医药学会 ,辽宁中医药大学

中华中医药学刊

CSTPCD北大核心
影响因子:1.007
ISSN:1673-7717
年,卷(期):2024.42(6)
  • 32